

**MASSACHUSETTS GENERAL HOSPITAL
DEPARTMENT OF ORTHOPAEDIC SURGERY**

GRAND ROUNDS

Carl A. Deirmengian, MD

Associate Professor, Department of Orthopaedic Surgery

Thomas Jefferson University

Rothman Orthopaedics

Chief of Orthopaedic Surgery, Lanenau Medical Center

Limerick, PA

***“The Discovery, Characterization, and
FDA-Authorization of the Alpha-defensin test for
Periprosthetic Infection”***



Thursday, January 30, 2020

6:45 am - 7:45 am



***Massachusetts General Hospital
O’Keeffe Auditorium***





Carl A. Deirmengian, MD is an Associate Professor of Orthopedic Surgery at Thomas Jefferson University at the Rothman Orthopaedics Institute, and Chief of Orthopaedic Surgery at Lankenau Medical Center. His clinical practice is focused on adult arthroplasty, including primary and revision hip and knee arthroplasty.

Dr. Deirmengian's undergraduate education was completed at Princeton University, where he received a degree in chemistry. He then attended Harvard Medical School where he gained an interest in orthopedic surgery, conducting basic science oncology research with Dr. Bruce Zetter and clinical orthopaedics research with Dr. Jesse Jupiter. Dr. Deirmengian then completed a residency in orthopedic surgery at the University of Pennsylvania, where he gained an interest in adult arthroplasty. He began research involving the diagnosis of periprosthetic infection and received the Mark Coventry Award from the Knee Society for his work identifying the neutrophil infection response to infection in synovial fluid. This interest in the diagnosis of infection continued through a fellowship in adult arthroplasty at Rush University Medical Center.

Upon starting his clinical practice, Dr. Deirmengian focused on research developing diagnostic tests for infection. CD Diagnostics was founded in 2009, at an incubator laboratory at the Lankenau Institute for Medical Research, with the mission of focusing a team of scientists to identify an optimal biomarker for periprosthetic joint infection. Multiple genomic and proteomic screens identified the antimicrobial peptide alpha-defensin, which 10 years later went on to become the first FDA-authorized diagnostic test in orthopedics in May of 2019. Dr. Deirmengian was chosen as the recipient of the 2020 Kappa Delta Elizabeth Winston Lanier Award from the AAOS for his work in "*The Discovery, Development, Characterization, and FDA Clearance of the Alpha-Defensin Test for Periprosthetic Infection.*"

He is married to Anne, also an orthopaedic surgeon, and has three children, Robert, Carl, and Elizabeth.

Thursday, January 30, 2020
Massachusetts General Hospital
Department of Orthopaedic Surgery

GRAND ROUNDS
O'Keeffe Auditorium
6:45 am - 7:45 am

6:45 am	Welcome	Hany Bedair, MD <i>Orthopaedic Surgeon Arthroplasty Service Newton Wellesley Joint Center Newton, MA Department of Orthopaedic Surgery Massachusetts General Hospital Boston, MA</i>
6:50 am	<i>"The Discovery, Characterization, and FDA-Authorization of the Alpha-defensin test for Periprosthetic Infection"</i>	Carl A. Deirmengian, MD
7:45 am	Wrap-up / Adjourn	Hany Bedair, MD